Astria Therapeutics, Inc. is a biotechnology company that is developing novel therapeutics for the treatment of cancer and other diseases. The company was founded in 2020 and is headquartered in Cambridge, Massachusetts. Astria's lead product candidate is a small molecule inhibitor of a protein called CD47, which is overexpressed in many types of cancer. The company is privately held and has not yet generated any revenue.